Formations et évènements

ESMO Congress 2022 Congress

09-13 septembre 2022

L'IFCT sera présent à l'ESMO 2022 avec 3 abstracts :

Nivolumab (Nivo) plus Ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced Non-Small-Cell-Lung Cancer (aNSCLC): results of the randomized IFCT-1701 phase 3 trial 
Gérard Zalcman (Bichat, APHP)
Date : Sunday 11 Sept 2022 (15:45 - 15:55) - Antibes Auditorium
Proffered paper session

Capmatinib for METex14 non-small cell lung cancer patients: results of the real-world study IFCT-2104 CapmATU
Marion Ferreira (CHU Tours)
Date : Saturday 10 Sept 2022

Increased incidence of thymic epithelial tumors during COVID-19 pandemic: A retrospective analysis from the French RYTHMIC network
Jose Carlos Benitez (Gustave Roussy, Villejuif)
Date : Saturday 10 Sept 2022

En savoir +

Site du congrès